| Business Summary | | Huntingdon
Life
Sciences
Group
plc
is
a
Contract
Research
Organization
that
provides
worldwide
pre-clinical
and
non-clinical
biological
safety
evaluation
research
services
to
most
of
the
world's
leading
pharmaceutical,
biotechnology,
agrochemical
and
industrial
chemical
companies.
Approximately
65%
of
the
Company's
orders
are
in
support
of
early
stage
development
of
promising
new
pharmaceutical
and
biotech
compounds.
The
purpose
of
this
safety
evaluation
is
to
identify
risks
to
humans,
animals
or
the
environment,
resulting
from
the
use
or
manufacture
of
a
wide
range
of
chemicals
that
are
essential
components
of
these
industries'
products.
Huntingdon's
services
are
designed
to
meet
the
regulatory
requirements
of
governments
around
the
world. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Huntingdon
Life
Sciences
is
a
Contract
Research
Organization
which
specializes
in
the
areas
of
non-clinical
safety
and
efficacy
testing
for
the
pharmaceutical,
biotechnology,
agrochemical
and
biotech
compounds
industries.
For
the
fiscal
year
ended
12/31/00,
revenues
increased
9%
to
L63.3
million.
Net
loss
rose
71%
to
L7M.
Revenues
reflect
the
impact
of
increased
orders
due
to
refinancing.
Higher
loss
reflects
an
increase
in
personnel
and
higher
foreign
exchange
losses. | More
from
Market Guide: Significant
Developments |
| Officers | | | FY2000 Pay | |
| Andrew Baker, 52 Chairman | $266K | Brian Cass, 53 COO,
Managing Director | 307K | Julian Griffiths, 48 Fin.
Director, Sec. | 115K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|